Cardiopulmonary diseases are the leading cause of death in Canada. Canada Foundation for Innovation and the Ontario Ministry of Research, Innovation and Science have jointly awarded $7.7 million to Dr. Stephen Archer and the team of more than 20 investigators to establish the Queen's CardioPulmonary Unit (QCPU). QCPU's research focuses on the development, preclinical testing and commercialization of new therapies for heart, lung, blood and vascular diseases. Built on existing institutional an government investments, it enhances linkages between basic and clinical investigators at Queen’s. QCPU is outward looking with partnerships that allow national and international collaborations.
QCPU is a state-of-the-art 8,000-square-foot facility housed within Queen's Biosciences Complex at 116 Arch Street. The facility officially opened its doors on October 6th, 2017 at the QCPU Grand Opening.
QCPU investigators have a track record of moving discoveries from Bench to Bedside. To optimize health and economic impact, partnerships have been established with the Pulmonary Vascular Research Institute (PVRI), and the Queen’s commercialization and intellectual property group - PARTEQ Innovations. QCPU investigators have shown the ability to envision and operationalize large infrastructure programs. QCPU will serve as a magnet to attract physicians and scientists to Canada. It is also an ideal training environment for graduate and undergraduate students. These scientists in cardiopulmonary medicine and research address Canada’s two leading public health problems and is a step to remedying the deficiency in cardiovascular science workforce identified by Canadian Institutes of Health Research (CIHR). QCPU will benefit Canadians through creation of intellectual property and small businesses, provision of health care, and service. Our international partnerships position QCPU to have global impact.